longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

Impedimed cancels lapsed options and performance rights, clarifying capital structure

Tip Ranks
Jul 3, 2026 at 05:24 AM
LongbridgeAII'm LongbridgeAI, I can summarize articles.

Impedimed Limited (AU:IPD) announced the lapse of 11,642,750 options and 8,529,911 performance rights due to unmet conditions. This reduces potential future dilution and clarifies the company's capital structure. The move aims to align reported capital with current realities and reset equity-based incentives. Analysts currently rate the stock as a Buy with a A$0.02 price target.

Impedimed Limited ( (AU:IPD) ) has issued an update.

Impedimed Limited has announced the cessation of 11,642,750 options and 8,529,911 performance rights after the conditions attached to these securities were not met or became incapable of being satisfied by 30 June 2026. The lapse of these conditional securities effectively reduces the company’s potential future dilution, clarifies its issued capital structure, and may signal a reset of its equity-based incentive arrangements for management and staff.

The move provides investors with greater transparency over Impedimed’s capital base and the status of its long-term incentive instruments. By formally recording the expiry of these options and performance rights, the company aligns its reported capital position with current realities, which may influence perceptions of future share supply and the alignment of executive incentives with shareholder interests.

The most recent analyst rating on (AU:IPD) stock is a Buy
with a A$0.02 price target.
To see the full list of analyst forecasts on Impedimed Limited stock,
see the AU:IPD Stock Forecast page.

More about Impedimed Limited

Impedimed Limited is an Australian-listed medical technology company, trading under the ASX code IPD. The company develops diagnostic and monitoring solutions, with its securities structure including options and performance rights tied to specific performance and vesting conditions for employees and stakeholders.

Average Trading Volume: 4,717,878

Technical Sentiment Signal: Sell

Current Market Cap: A$21.96M

Learn more about IPD stock on TipRanks’ Stock Analysis page.

Login to unlock1,143characters for free

Due to copyright restrictions, please log in to your Longbridge account to view this content.
Thank you for your understanding and support of licensed content.

Recommended Readings

  • Sep 10, 2026 at 08:54 AMAAPL: Memory Costs Surge, Price Hikes Loom — Can Foldables Save the Day?
  • Sep 10, 2026 at 08:58 AMOracle Q1 Preview: Stock Down 53% From Record High, Analyst Says Buy and Hold — 'A Decade Stock'
Impedimed Limited

Impedimed Limited

IPD.AU

Open

--

High

--

Low

--

Prev Close

--

P/ETTM

--

Market Cap

--

LongbridgeAI